Copyright: ©Author(s) 2026.
World J Psychiatry. Jul 19, 2026; 16(7): 117803
Published online Jul 19, 2026. doi: 10.5498/wjp.117803
Published online Jul 19, 2026. doi: 10.5498/wjp.117803
Table 1 Baseline characteristics, mean ± SD
| GAD group | Control group | P value | t/F | |
| Age (years) | 35.00 ± 11.02 | 33.65 ± 12.35 | 0.717 | -0.365 |
| Gender (male/female) | 4/16 | 9/11 | 0.088 | 1.000 |
| Disease course (months) | 31.55 ± 20.62 | |||
| HAMA | 23.95 ± 4.52 | |||
| SAS | 55.69 ± 4.22 | |||
| PSQI | 12.65 ± 3.588 |
Table 2 Comparison of primary and secondary outcome indicators, mean ± SD
| Before treatment | After treatment | P value | t | ||
| Primary | HAMA | 23.95 ± 4.52 | 9.75 ± 5.94 | 0.000 | 13.33 |
| Secondary | SAS | 55.69 ± 4.22 | 36.88 ± 6.70 | 0.000 | 12.15 |
| PSQI | 12.65 ± 3.59 | 6.05 ± 2.80 | 0.000 | 10.08 |
- Citation: Zhang J, Li WB, Wang XX, Han TT, Dong S, Sang YN, Lu M, Guo XH. Congqi Shoushen Tuina Method for generalized anxiety disorder: Clinical outcomes and serum metabolomic profiles. World J Psychiatry 2026; 16(7): 117803
- URL: https://www.wjgnet.com/2220-3206/full/v16/i7/117803.htm
- DOI: https://dx.doi.org/10.5498/wjp.117803